Jeffrey M. Jonas - 17 Feb 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Innovation Officer, Director
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol: SAGE
Transactions as of: 17 Feb 2022
Net transactions value: +$1,800
Form type: 4
Filing time: 18 Feb 2022, 15:10:27 UTC
Previous filing: 15 Feb 2022
Next filing: 29 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Options Exercise	$1,800	+4,000	+4.9%	$0.4500^*	84,863	17 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Option (Right to Buy)	Options Exercise	$0	-4,000	-8.6%	$0.000000	42,587	17 Feb 2022	Common Stock	4,000	$0.4500	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017.